pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Sep 1·1 min read
save

ARCH Venture Partners aims to raise $3 billion for its 14th biotech fund

Sep 1, 2026·read at Endpoints ↗DealNeutral

ARCH Venture Partners, a leading biotech venture capital firm, announced its intention to raise about $3 billion for a new fund.

The proposed fund would be the firm's 14th and would rank among the largest venture capital raises in the biotech sector.

The move underscores continued investor appetite for biotech startups despite market volatility, and could provide significant capital for emerging companies.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “ARCH Venture Partners targets $3 billion raise for latest fund”

read at Endpoints ↗
83 words · retrieved Sep 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING

related stories

  • May 4Opinion: Are blue zones real? Answering that question is harder than everSTAT
  • May 2Federal appeals court blocks mailing of abortion pill mifepristoneSTAT
  • May 1Arvinas’ ‘Protac’ breast cancer drug cleared by FDABioPharma Dive
  • Apr 30Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstoodSTAT
  • Apr 30Merck still sees ‘compelling’ outlook for Terns leukemia drugBioPharma Dive